Ardelyx (ARDX) Revenue Growth (3y) (2018 - 2026)
Ardelyx (ARDX) Revenue Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 54.05% |
| 10 | Ardelyx | 1.27 Bn | 1.03 Bn | 89.66 Mn | 102.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.55% |
| Dec 31, 2025 | 41.52% |
| Sep 30, 2025 | -11.98% |
| Jun 30, 2025 | 238.14% |
| Mar 31, 2025 | 441.03% |
| Dec 31, 2024 | 383.25% |
| Sep 30, 2024 | 337.52% |
| Jun 30, 2024 | 282.05% |
| Mar 31, 2024 | 91.22% |
| Dec 31, 2023 | 166.82% |
| Sep 30, 2023 | 174.95% |
| Jun 30, 2023 | 129.98% |
| Mar 31, 2023 | 110.84% |
| Dec 31, 2022 | 169.78% |
| Sep 30, 2022 | 18.28% |
| Jun 30, 2022 | 419.66% |
| Dec 31, 2021 | 129.61% |
| Sep 30, 2021 | 89.64% |
| Jun 30, 2021 | 252.41% |
| Mar 31, 2021 | 41.57% |